Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome
Sign Up to like & getrecommendations! Published in 2018 at "BMC Pharmacology & Toxicology"
DOI: 10.1186/s40360-018-0202-9
Abstract: BackgroundThe efficacy of tacrolimus (TAC) is variable in the treatment of nephrotic syndrome (NS), which might be related to genetic variation among patients. Therefore, we aim to investigate the effects of CYP3 A4, CYP3 A5… read more here.
Keywords: clinical efficacy; gene polymorphisms; efficacy; cyp3 ... See more keywords